N-3C01 / Hefei Xinzhu Biological Technology - LARVOL DELTA

N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=114 | Recruiting | Sponsor: Hefei Xinzhu Biological Technology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Colorectal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck